Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2018-03-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
中勤万信关于安图生物2017年度募集资金存放与使用情况专项审核报告
Regulatory Filings
2018-03-27 Chinese
关联交易决策制度
Governance Information Classification · 95% confidence The document is titled '郑州安图生物工程股份有限公司 关联交易决策制度' which translates to 'Zhengzhou Antu Bioengineering Co., Ltd. Related Party Transaction Decision System'. It details the internal rules, procedures, and governance related to related party transactions within the company, including definitions of related parties, approval processes, disclosure requirements, and voting procedures. There is no indication of financial statements, audit results, earnings data, or regulatory announcements. The content focuses on governance practices and internal control mechanisms regarding related party transactions. Therefore, this document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2018-03-27 Chinese
关于修订《总经理工作细则》的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding revisions to the "General Manager Work Rules." It details changes to internal management policies and authority of the general manager, referencing compliance with company law and company articles. There is no financial data, no mention of financial results, no regulatory filings like 10-K or interim reports, and no shareholder voting results. The document is a corporate governance update about internal management rules, which fits best under Board/Management Information (MANG). The document length is short (2292 characters), and it is not a report publication announcement or certification. Therefore, the classification is Board/Management Information (MANG).
2018-03-27 Chinese
关于召开2017年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2017 Annual General Meeting (AGM) of Zhengzhou Antu Bioengineering Co., Ltd., including details about the meeting date, voting methods, agenda items, and proxy authorization. It does not contain the actual annual report or financial statements but rather the announcement and procedural information related to the AGM. The document length is 3490 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2018-03-27 Chinese
独立董事关于对公司第二届董事会第十八次会议相关事项的独立意见
AGM Information Classification · 95% confidence The document is an independent director's opinion on several matters to be submitted to the shareholders' meeting, including dividend distribution, director and supervisor remuneration, and auditor reappointment. It references the company's articles of association, relevant laws, and audit firm appointment for the 2018 fiscal year. The document is short (858 characters) and does not contain financial statements or detailed financial data. It is a formal opinion related to items to be voted on at a shareholders' meeting, consistent with materials typically presented in AGM contexts. Therefore, this document fits best as AGM Information (AGM-R).
2018-03-27 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 郑州安图生物工程股份有限公司. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, and other governance matters. It is a comprehensive internal governance document rather than a financial report, announcement, or meeting material. There is no indication that this is an Annual Report, Audit Report, or any other financial or regulatory filing. The content aligns with governance information about the company's internal rules and structure. Therefore, the appropriate classification is Governance Information (CGR). The document length is substantial and contains detailed governance provisions, confirming it is not a brief announcement or a report publication notice.
2018-03-27 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.